{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:16:35Z","timestamp":1727842595202},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"DOI":"10.7759\/cureus.70622","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:22:34Z","timestamp":1727788954000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Dose Escalation of Imatinib in Chronic Myeloid Leukemia Patients: A Retrospective Analysis From an Indian University Teaching Hospital"],"prefix":"10.7759","author":[{"given":"Rajan","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kajal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","unstructured":"Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960, 132:1497.","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker BJ","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al.. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344:1031-7. 10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian H","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al.. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346:645-52. 10.1056\/NEJMoa011573","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al.. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362:2260-70. 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study","volume":"113","author":"Baccarani M","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F, et al.. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study. Blood. 2009, 113:4497-504. 10.1182\/blood-2008-12-191254","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani M","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al.. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013, 122:872-84. 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"ref7","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (2009). https.\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53:457-81.","journal-title":"J Am Stat Assoc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-\u03b1","volume":"102","author":"Cortes J","year":"2003","unstructured":"Cortes J, Giles F, O'Brien S, et al.. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-\u03b1. Blood. 2003, 102:83-6. 10.1182\/blood-2003-01-0025","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah NP","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004, 305:399-401. 10.1126\/science.1099480","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study","volume":"99","author":"Talpaz M","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, et al.. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood. 2002, 99:1928-37. 10.1182\/blood.v99.6.1928","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson RA","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, et al.. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012, 26:2197-203. 10.1038\/leu.2012.134","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94 Suppl 2","author":"Baccarani M","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015, 94 Suppl 2:S141-7. 10.1007\/s00277-015-2322-2","journal-title":"Ann Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm","volume":"15","author":"Jabbour E","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015, 15:323-34. 10.1016\/j.clml.2015.03.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al.. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016, 30:1044-54. 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley JF","year":"2007","unstructured":"Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-29. 10.1016\/S1470-2045(07)70342-X","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293518-outcomes-of-dose-escalation-of-imatinib-in-chronic-myeloid-leukemia-patients-a-retrospective-analysis-from-an-indian-university-teaching-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:22:36Z","timestamp":1727788956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293518-outcomes-of-dose-escalation-of-imatinib-in-chronic-myeloid-leukemia-patients-a-retrospective-analysis-from-an-indian-university-teaching-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.70622","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}